ROMY

Romiplostim 250 mcg is a recombinant human thrombopoietin receptor agonist used to treat Immune Thrombocytopenia (ITP), a condition characterized by an abnormally low platelet count, which increases the risk of bleeding and bruising. By stimulating the thrombopoietin receptor, Romiplostim encourages the production of platelets in the bone marrow.

Romiplostim is typically prescribed for patients with chronic ITP who have not responded well to corticosteroids or immunoglobulin therapy, or for those who are dependent on other treatments but need an alternative.

Uses of Romiplostim

✅ Chronic ITP — For patients who do not respond to standard treatments such as corticosteroids or immunoglobulins.
✅ Low Platelet Counts — In patients requiring increased platelet production for safety and reduced bleeding risks.
✅ Platelet Count Management — Used to maintain platelet counts within a safe range to minimize bleeding complications.

Key Benefits

• Increases platelet production: Stimulates the bone marrow to produce more platelets.

• Reduces bleeding risk: Elevates platelet counts, decreasing the risk of bruising and bleeding.

• Non-surgical option: Avoids the need for invasive treatments like splenectomy.

• Well-established efficacy: Proven results in clinical trials for improving platelet counts.

How Romiplostim Works

Romiplostim binds to and activates the thrombopoietin receptor on bone marrow cells, thereby stimulating the production of platelets. It mimics the natural action of thrombopoietin, a protein that plays a key role in platelet production. By promoting the maturation and release of platelets from megakaryocytes (precursor cells), Romiplostim helps restore normal platelet levels in the bloodstream.